Company news

9 articles on ABBV

1. ABBVOct 23, 2026Company release
   U.S. FDA approves subcutaneous induction for AbbVie's SKYRIZI in Crohn's disease

   The induction doses are given by on-body injector at weeks 0, 2, 4 and 8, followed by maintenance doses every eight weeks starting at week 12.

2. ABBVOct 18, 2026Company release
   AbbVie to present new and updated data at 2026 ESMO Congress in Madrid

   The presentations cover seven assets across lung, colorectal, ovarian, prostate and gastric cancers.

3. ABBVOct 17, 2026Company release
   AbbVie presents 20 IBD abstracts with long-term Skyrizi and Rinvoq data at UEGW 2026

   The company said the meeting runs October 17 to 20 in Barcelona, Spain, and includes new endoscopic remission data for investigational ABBV-466 in Crohn's disease.

4. ABBVOct 11, 2026Company release
   AbbVie to present 22 inflammatory bowel disease abstracts at ACG 2026 meeting

   AbbVie said new Phase 3 AFFIRM data showed higher clinical and endoscopic response rates for subcutaneous SKYRIZI than placebo in Crohn's disease patients.

5. ABBVOct 7, 2026Company release
   AbbVie's Temab-A receives two FDA Breakthrough Therapy Designations

   The designations cover colorectal cancer and non-small cell lung cancer, and are the first for the drug.

6. ABBVOct 1, 2026Company release
   AbbVie presents continued repigmentation data for RINVOQ in non-segmental vitiligo

   The late-breaking data from the Phase 3 Viti-Up-1 and Viti-Up-2 studies were presented at the 2026 EADV Congress in Vienna, Austria.

7. ABBVSep 30, 2026Company release
   AbbVie presents Phase 1 data for obesity candidate ABBV-295 at EASD 2026

   AbbVie said the findings support advancing ABBV-295 into Phase 2 development for chronic weight management.

8. ABBVSep 30, 2026Company release
   AbbVie zumilokibart Phase 2 study meets primary endpoint in atopic dermatitis

   The mid-dose regimen was selected for Phase 3 development, the company said.

9. ABBVSep 28, 2026Company release
   U.S. FDA approves AbbVie's JUVMO (tavapadon) for Parkinson's disease

   The tablets are taken once daily, with or without levodopa therapy, the company said.